258 related articles for article (PubMed ID: 22729393)
1. Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea.
Kang RY; Lee J; Lee YH; Lee HS; Jeong JH; Lee YJ
Int J Clin Pharm; 2012 Aug; 34(4):651-7. PubMed ID: 22729393
[TBL] [Abstract][Full Text] [Related]
2. Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions.
Vadhan-Raj S; Zhou X; Sizer K; Lal L; Wang X; Roquemore J; Shi W; Benjamin RS; Lichtiger B
Oncologist; 2010; 15(12):1359-69. PubMed ID: 21159724
[TBL] [Abstract][Full Text] [Related]
3. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
[TBL] [Abstract][Full Text] [Related]
4. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia.
Ferrajoli A; Buzdar AU; Dejesus Y; Cheng L; Michaud LB; Rodriguez MA
Cancer; 2011 Jul; 117(14):3268-75. PubMed ID: 21264831
[TBL] [Abstract][Full Text] [Related]
5. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
Winkelmayer WC; Mitani AA; Goldstein BA; Brookhart MA; Chertow GM
JAMA Intern Med; 2014 May; 174(5):699-707. PubMed ID: 24589911
[TBL] [Abstract][Full Text] [Related]
6. Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013.
Xu L; Xu H; Cannavale K; Sattayapiwat O; Rodriguez R; Page JH; Chao C
Support Care Cancer; 2016 Jul; 24(7):2989-98. PubMed ID: 26872791
[TBL] [Abstract][Full Text] [Related]
7. Trends in Erythropoiesis-stimulating agent use and blood transfusions for chemotherapy-induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle.
Vega A; Zhang R; Wong HL; Wernecke M; Alexander M; Feng Y; Lo AC; Lufkin B; Ryan Q; Izem R; MaCurdy TE; Kelman JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2021 May; 30(5):626-635. PubMed ID: 33534188
[TBL] [Abstract][Full Text] [Related]
8. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
[TBL] [Abstract][Full Text] [Related]
9. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
[TBL] [Abstract][Full Text] [Related]
10. On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.
Seetasith A; Holdford D; Shah A; Patterson J
Res Social Adm Pharm; 2017; 13(4):778-788. PubMed ID: 27595426
[TBL] [Abstract][Full Text] [Related]
11. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
12. Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece.
Papachristos A; Kani C; Litsa P; Valsami G; Souliotis K; Saridi M; Markantonis S
Consult Pharm; 2016 May; 31(5):271-81. PubMed ID: 27178657
[TBL] [Abstract][Full Text] [Related]
13. Impact of a Patient Blood Management Program and an Outpatient Anemia Management Protocol on Red Cell Transfusions in Oncology Inpatients and Outpatients.
Gross I; Trentino KM; Andreescu A; Pierson R; Maietta RA; Farmer S
Oncologist; 2016 Mar; 21(3):327-32. PubMed ID: 26865590
[TBL] [Abstract][Full Text] [Related]
14. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
[TBL] [Abstract][Full Text] [Related]
15. Chinese physician perception on the treatment of chemotherapy-induced anemia: online cross-section survey study.
Zhang J; Du Y; Meng Y; Liu X; Mu Y
Chin Clin Oncol; 2024 Feb; 13(1):5. PubMed ID: 38453656
[TBL] [Abstract][Full Text] [Related]
16. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.
Aapro M; Jelkmann W; Constantinescu SN; Leyland-Jones B
Br J Cancer; 2012 Mar; 106(7):1249-58. PubMed ID: 22395661
[TBL] [Abstract][Full Text] [Related]
17. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
18. Erythropoiesis-stimulating agents as replacement therapy for blood transfusions in critically ill patients with anaemia: A systematic review with meta-analysis.
Wijnberge M; Rellum SR; de Bruin S; Cecconi M; Oczkowski S; Vlaar AP
Transfus Med; 2020 Dec; 30(6):433-441. PubMed ID: 32935404
[TBL] [Abstract][Full Text] [Related]
19. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin or darbepoetin for patients with cancer.
Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]